Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
Harpoon Therapeutics, Inc. recently provided a pipeline milestone update on its TriTAC development programs.
“We are excited to begin 2022 with a catalyst rich year that will be driven by our multiple TriTAC clinical programs, including advancing our HPN217 program into the next phase of development,” stated Julie Eastland, President and CEO, Harpoon Therapeutics. “We also expect to submit our first IND for HPN601, targeting EpCAM, from our ProTriTAC technology platform as well as advance an additional preclinical candidate into IND enabling studies as we continue to build out our future clinical pipeline.”
Anticipated 2022 Milestones
TriTAC Clinical Programs
- HPN328 – Continue dose escalation to determine RP2D by year-end 2022
- HPN217 – Select the RP2D and initiate dose expansion cohort during the first half of 2022
- HPN536 – Complete dose escalation by year-end 2022
- HPN424 – Complete dose escalation during the second half of 2022
Platform Technologies & Next Clinical Candidate
- HPN601 – IND submission by year-end 2022
- Platform technologies – Advance a clinical candidate into IND enabling studies during the second half of 2022
Corporate Update Events
- Harpoon will host an R&D Day during the first half of 2022
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. Harpoon has also developed a proprietary ProTriTAC platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For more information, visit www.harpoontx.com.
Total Page Views: 644
